A placebo-controlled study of psychedelics reveals the psychological benefits of microdosing are most likely explained by the placebo effect.
Is it possible to have a psychedelic experience from taking a placebo alone? A new study says it is.
Cortice Biosciences announced today results from placebo-controlled, double-blinded Phase 1 studies evaluating TPI 287, a brain penetrable microtubule stabilizing agent, for the treatment of Alzheimer’s disease, progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS).
Researchers reveal how our brain's reward system tricks us into thinking a more expensive bottle of wine tastes better.
Clinical trials show that a new drug called ocrelizumab can reduce attacks in people with RRMS, and can reduce new symptom development in patients with primary progressive multiple sclerosis.
Researchers believe their finding could usher in a new era of personalized interventions to help chronic pain sufferers.
A new study argues that clinical improvements reported as being the result of neurofeedback are more likely due to a placebo effect.
According to a new study, lithium appears to be safe and effective in treating bipolar disorder in children, at least in the short term.
A new study reports how well people with depression respond to placebos may determine how well they will respond to antidepressant medications.
According to a new study, even when people are aware they are taking a placebo, they still feel relief from pain.
Researchers examine the effect genomics is having on placebos in research and patient care.
